Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Definitive biomarkers for both differentiating neurodegenerative diseases and monitoring their progression over time are sorely needed. This has become particularly crucial for the development of therapies targeting core disease mechanisms.2 β-Amyloid (Aβ) and associated biomarkers have revolutionised current thoughts and theories on Alzheimer's disease (AD) with the hope that significant advances in clinical therapies can now be achieved.2 The most significant change is their use to detect asymptomatic disease due to many disappointing clinical trials in definitively diagnosed symptomatic patients.3 This change in thinking has only been possible in AD due to advances in imaging and peripheral biomarker research and their application in diverse population settings.4 To date the identification of definitive biomarkers for other neurodegenerative …
The hunt for objective biomarkers for neurodegenerative disorders is starting to pay dividends, with a reduction rather than increase in CSF τ levels identified by Wagshal et al1 in patients with progressive supranuclear palsy (PSP).
Competing interests None.
Provenance and peer review Commissioned; internally peer reviewed.